➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Merck
Boehringer Ingelheim
Dow
AstraZeneca

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Patent: 10,213,420

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,213,420
Title:Combination therapy for treatment of HBV infections
Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
Inventor(s): Hartman; George D. (Lansdale, PA)
Assignee: NOVIRA THERAPEUTICS, INC. (Doylestown, PA)
Application Number:15/284,807
Patent Claims:see list of patent claims

Details for Patent 10,213,420

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec Inc PLEGRIDY peginterferon beta-1a INJECTABLE;INJECTION 125499 001 2014-08-15   Start Trial NOVIRA THERAPEUTICS, INC. (Doylestown, PA) 2034-02-05 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial NOVIRA THERAPEUTICS, INC. (Doylestown, PA) 2034-02-05 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial NOVIRA THERAPEUTICS, INC. (Doylestown, PA) 2034-02-05 RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial NOVIRA THERAPEUTICS, INC. (Doylestown, PA) 2034-02-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKesson
Merck
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.